NIR-light triggered dual-cascade targeting core-shell nanoparticles enhanced photodynamic therapy and immunotherapy

Wei, Dengshuai; Han, Yan; Huang, Yun; Peng, Li; Zhao, Yao; Zhang, Xianghong; Wan, Jia; Yin, Xiangye; Liu, Tang; Yin, Ji‐Ye; Liu, Zhao‐Qian; Zhang, Qi; Wang, Jianliu; Xiao, Haihua

doi:10.1016/j.nantod.2021.101288

Cited by 63 publications

(39 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, NP@Pt-1 + L demonstrated a potent ability to promote DC maturation compared to the other treatment groups, suggesting the necessity of light irritation of NP@Pt-1 for DCs maturation. To evaluate the side effect, the amount of proliferative effector killer T cells (CD3 + CD8 + ) in the spleen were measured [ 30 , 31 ]. Notably, the results showed there was no significant increase in the amount of CD8 + T cells in the spleen of mice treated with NP@Pt-1 + L (Fig.…”

Section: Resultsmentioning

confidence: 99%

Light triggered release of a triple action porphyrin-cisplatin conjugate evokes stronger immunogenic cell death for chemotherapy, photodynamic therapy and cancer immunotherapy

Song

Cai

et al. 2022

J Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has emerged as an attractive therapeutic approach which can elicit immunogenic cell death (ICD). However, current ICD inducers are still very limited as the representative ICD induces of photosensitizers can only evoke insufficient ICD to achieve unsatisfactory cancer immunotherapy. Herein, we demonstrated the use of a triple action cationic porphyrin-cisplatin conjugate (Pt-1) for drug delivery by a reactive oxygen species (ROS) sensitive polymer as nanoparticles (NP@Pt-1) for combined chemotherapy, PDT and immunotherapy. This unique triple action Pt-1 contains both chemotherapeutic Pt drugs and Porphyrin as a photosensitizer to generate ROS for PDT. Moreover, the ROS generated by Pt-1 can on the one hand degrade polymer carriers to release Pt-1 for chemotherapy and PDT. On the other hand, the ROS generated by Pt-1 subsequently triggered the ICD cascade for immunotherapy. Taken together, we demonstrated that NP@Pt-1 were the most effective and worked in a triple way. This study could provide us with new insight into the development of nanomedicine for chemotherapy, PDT as well as cancer immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Light triggered release of a triple action porphyrin-cisplatin conjugate evokes stronger immunogenic cell death for chemotherapy, photodynamic therapy and cancer immunotherapy

Song

Cai

et al. 2022

J Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

show abstract

“…As illustrated in Figure 12 A, Wei et al 76 developed a nanodelivery system that can be controlled by NIR to achieve cascade targeting of cancer cells and immune cells. In this study, they synthesized three types of polymers by polycondensation, namely, degradable infrared two-zone fluorescent polymer P1, triphenylphosphine polymer P2 with mitochondrial targeting, and polymer P3, whose thione structure can be destroyed in the presence of ROS.…”

Section: Subcellular-targeted Pdtmentioning

confidence: 99%

“… (A) Design of core shell nanoparticles and illustration with dual-cascade targeting (DCT) performance triggered by NIR light for maximizing the efficacy of photodynamic therapy (PDT) and cancer immunotherapy. Adapted with permission from 76 , copyright 2021 Elsevier. …”

Section: Figurementioning

confidence: 99%

How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?

Zhang

Zhao

et al. 2022

Theranostics

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a promising method of tumor ablation and function-preserving oncological intervention, which is minimally invasive, repeatable, and has excellent function and cosmetic effect, with no cumulative toxicity. More importantly, PDT can induce immunogenic cell death and local inflammation, thus stimulating the body's immune response. However, the weak immunity induced by PDT alone is insufficient to trigger a systemic immune response towards cancer cells. To overcome this obstacle, multiple strategies have been investigated, including tumor microenvironment remodeling, tumor vaccines, subcellular-targeted PDT, and synergistic therapies. This review summarizes the latest progress in the development of strategies to improve the PDT-induced immune effect for enhanced cancer treatment.

show abstract

“…Photodynamic therapy (PDT) is a promising anti-tumor therapy with high effectiveness and low incidence of adverse effects. [2][3][4] Recent studies unveil PDT can efficiently kill tumor cells through photodynamic-immunotherapy. [3][4][5] However, there is still SRDD which hampered the efficient delivery of photosensitizers (PSs) to exert PDT.…”

Section: Introductionmentioning

confidence: 99%

“…[2][3][4] Recent studies unveil PDT can efficiently kill tumor cells through photodynamic-immunotherapy. [3][4][5] However, there is still SRDD which hampered the efficient delivery of photosensitizers (PSs) to exert PDT. Therefore, it is of great significance to deliver PSs to cancer cells and even organelles before they are irradiated.…”

Section: Introductionmentioning

confidence: 99%

Targeting Bone Tumor and Subcellular Endoplasmic Reticulum via Near Infrared II Fluorescent Polymer for Photodynamic‐Immunotherapy to Break the Step‐Reduction Delivery Dilemma

Zhang

Wan

et al. 2022

Advanced Science

Self Cite

View full text Add to dashboard Cite

Specific localization of photosensitizers (PSs) to a certain organelle could result in targeted attack to cause greater trauma to cancer cells, eventually maximizing photodynamic therapy (PDT). However, currently, efficient and precise transportation of PSs via drug delivery to tumor cells and subcellular organelles is still challenging, due to a so‐called step‐reduction delivery dilemma (SRDD) which also threatens anticancer drug delivery to exert their efficacy. Herein, a cascade targeting near infrared II (NIR II) fluorescent nanoparticles (NPER/BO‐PDT) is designed that can target bone tumor first and then target the subcellular organelle of endoplasmic reticulum (ER). It is found that NPER/BO‐PDT achieves the targeted accumulation of the bone tumor and then ER. NPER/BO‐PDT generates reactive oxygen species (ROS) in the subcellular organelles of ER under near infrared light irradiation. The continuous ER stress by ROS promotes the release of more damage‐associated molecular patterns, induces immunogenic cell death, stimulates the adaptive immune response, and further synergistically inhibits tumor growth, achieving the so‐called photodynamic‐immunotherapy. Overall, this study exemplifies a safe and efficient nano‐drug delivery system for a bone and ER cascade targeting via delivery of PSs to break the SRDD and highlights potential clinical translation.

show abstract

NIR-light triggered dual-cascade targeting core-shell nanoparticles enhanced photodynamic therapy and immunotherapy

Cited by 63 publications

References 32 publications

Light triggered release of a triple action porphyrin-cisplatin conjugate evokes stronger immunogenic cell death for chemotherapy, photodynamic therapy and cancer immunotherapy

Light triggered release of a triple action porphyrin-cisplatin conjugate evokes stronger immunogenic cell death for chemotherapy, photodynamic therapy and cancer immunotherapy

How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?

Targeting Bone Tumor and Subcellular Endoplasmic Reticulum via Near Infrared II Fluorescent Polymer for Photodynamic‐Immunotherapy to Break the Step‐Reduction Delivery Dilemma

Contact Info

Product

Resources

About